Almirall Focus Firmly On Lebrikizumab After Securing Klisyri Approval

Big Quarter Ahead For Spanish Group

 
• By Kevin Grogan

Now that the actinic keratosis treatment Klisyri has got the green light in Europe, the Spanish firm's attention will be on atopic dermatitis and forthcoming Phase III data on lebrikizumab, a potential rival to Dupixent.

Almirall headquarters
Big quarter coming up for the Barcelona-based firm • Source: Archive

More from New Products

More from Scrip